Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 17/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130801 | 0.86 | EGLN1 (0.47) | P2RX3 | |
| SCHEMBL2131794 | 0.84 | KDM4E (0.45) | LTA4HPTGS2P2RX3 | |
| SCHEMBL2135295 | 0.77 | P2RX3 (0.42) | P2RX3 | |
| SCHEMBL2131801 | 0.77 | HCRTR1 (0.48) | CHRM5LTA4HP2RX3 | |
| SCHEMBL5963434 | 0.75 | L3MBTL1 (0.49) | — | |
| SCHEMBL14577578 | 0.73 | CHRM5 (0.59) | CHRM5LTA4HPTGS2 | |
| SCHEMBL4238868 | 0.71 | PDE10A (0.55) | — | |
| SCHEMBL646795 | 0.71 | LTA4H (0.50) | CHRM5LTA4HPTGS2P2RX3 | |
| SCHEMBL6158569 | 0.71 | SMN1; SMN2 (0.48) | CHRM5P2RX3 | |
| SCHEMBL2896362 | 0.71 | FADS1 (0.48) | CHRM5LTA4HP2RX3MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | HCRTR2, HCRTR1, NPY4R | CHRM5 356/4885LTA4H 735/4885PTGS2 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.